Establishes the Wholesale Prescription Drug Importation Program for the importation of wholesale prescription drugs from Canada, to provide savings to Rhode Island consumers.
H5853 would create a new Wholesale Prescription Drug Importation Program within Rhode Island law, authorizing the state to import certain prescription drugs from Canada on a wholesale basis for use in the state. The program is intended to lower drug costs for Rhode Island consumers and would only move forward if the U.S. Department of Health and Human Services approves and certifies the program under federal law. The bill directs the executive office of health and human services to design the program, identify a state agency or licensed wholesaler to operate it, and ensure that imported drugs meet federal safety and effectiveness standards.
The bill lays out a detailed framework for implementation. It requires rules by January 1, 2026, a federal approval request by May 1, 2026, and operation within six months after federal certification. The program must use Canadian suppliers regulated by Canadian law, limit imports to drugs expected to produce substantial savings, comply with federal tracking and tracing requirements, prohibit resale outside Rhode Island, and include financing, auditing, outreach, and public price transparency measures. Annual reports to legislative leaders would track participating entities, drugs dispensed, and estimated savings.
If enacted, H5853 would add a new chapter to Title 21 of the General Laws governing food and drugs and would give the executive office of health and human services responsibility for designing and overseeing the importation program. It would also require the state to work with a licensed drug wholesaler or become one itself, contract with Canadian suppliers and in-state distributors, and establish a public website, hotline, and audit process. The bill would affect state agencies, pharmacies, health insurers, employers, health care providers, and consumers, but only after federal certification is obtained; until then, the program cannot be implemented.
The bill’s stated purpose and structure suggest a generally favorable policy approach centered on reducing prescription drug costs for residents. The bill text emphasizes consumer savings, safety safeguards, and administrative oversight, and the available context identifies the measure as a cost-saving importation proposal. No committee transcript or vote record is available here, so there is no documented debate or recorded opposition in the provided materials.
The main points of potential contention are likely to be federal approval, drug safety, and the practical feasibility of importing prescription drugs from Canada. The bill requires compliance with federal importation law and HHS certification before implementation, which reflects legal uncertainty and regulatory dependence. Other likely concerns include whether the program will actually generate meaningful savings, how start-up and operating costs will be funded without reducing savings, and whether the state can effectively manage wholesaler, tracing, and audit obligations. Stakeholders most directly affected would include state health officials, pharmacies, insurers, employers, providers, and consumers, though no specific opposing or supporting groups are identified in the record provided.